E. Ohman J or Asset Management AB Acquires 500 Shares of Illumina, Inc. (NASDAQ:ILMN)

E. Ohman J or Asset Management AB increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,965 shares of the life sciences company’s stock after purchasing an additional 500 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Illumina were worth $931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ILMN. Cetera Investment Advisers grew its stake in shares of Illumina by 25.8% in the second quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after purchasing an additional 3,767 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Illumina by 31.1% in the third quarter. GAMMA Investing LLC now owns 2,919 shares of the life sciences company’s stock worth $381,000 after buying an additional 692 shares during the period. Azzad Asset Management Inc. ADV lifted its holdings in Illumina by 8.1% in the third quarter. Azzad Asset Management Inc. ADV now owns 4,235 shares of the life sciences company’s stock worth $552,000 after buying an additional 317 shares during the period. Diversified Trust Co purchased a new stake in Illumina in the third quarter worth about $243,000. Finally, Axiom Advisory LLC lifted its holdings in Illumina by 3.2% in the third quarter. Axiom Advisory LLC now owns 6,528 shares of the life sciences company’s stock worth $805,000 after buying an additional 204 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 0.4 %

Shares of ILMN stock opened at $124.68 on Thursday. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The firm has a fifty day moving average price of $138.19 and a 200-day moving average price of $135.50. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market cap of $19.77 billion, a price-to-earnings ratio of -12.52 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the firm posted $0.33 EPS. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 4.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. Piper Sandler lowered their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus target price of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.